Close

Bausch Health Co. Inc. (BHC) Dermatology Unit, Ortho Dermatologics, Reports Statistically Significant Topline Results From 2nd Pivotal Ph. 3 Clinical Trial Evaluating IDP-126 Gel In Acne Vulgaris

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/24/2024

1. TSLA
2. ENPH
3. TXN
4. BA
5. SPOT
6. META
7. V
8. IBM
9. KMB
10. HCP


Go back to Bausch Health Co. Inc. (BHC) Dermatology Unit, Ortho Dermatologics, Reports Statistically Significant Topline Results From 2nd Pivotal Ph. 3 Clinical Trial Evaluating IDP-126 Gel In Acne Vulgaris

Ortho Dermatologics Announces Statistically Significant Topline Results From Second Pivotal Phase 3 Clinical Trial Evaluating IDP-126 Gel In Acne Vulgaris

April 22, 2021 6:59 AM EDT

All Three Co-Primary Endpoints Were Achieved

LAVAL, QC, April 22, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced statistically... More